<DOC>
	<DOCNO>NCT02757703</DOCNO>
	<brief_summary>Various vasoactive drug recommend use combination endoscopic variceal ligation ( EVL ) treat acute esophageal variceal bleeding ( EVB ) . The efficacy drug choice vasoactive agent Taiwan 's National Health Insurance program remain validate . The aim prospective cohort study assess efficacy somatostatin , compare terlipressin cirrhotic patient acute EVB receive EVL preference vasoactive agent real-world clinical practice . From April 2010 April 2015 , cirrhotic patient significant upper gastrointestinal bleeding screen . Eligible patient acute EVB non-randomly assign receive early administration somatostatin ( group S ) terlipressin ( group T ) infusion , follow EVL . A decision use vasoactive drug depend physician 's favorite . In group S , somatostatin intravenous bolus ( 250 μg ) follow 250 μg/hour continue 3 day . In group T , terlipressin start 2mg bolus injection follow 1 mg infusion every 6 hour 3 day .</brief_summary>
	<brief_title>Vasoactive Drugs Real World Practice</brief_title>
	<detailed_description>Introduction Rupture esophageal varix result variceal hemorrhage major complication cirrhotic patient lead high mortality rate . Despite control initial bleeding , early rebleeding may high 30-50 % among survived patient mortality rate 40 % . Therefore recommended goal place bleed arrest prevention early rebleeding . Vasoactive drug may reduce portal hypertension lead reduction variceal pressure achieve good control hemorrhage . In general , vasoactive agent profoundly improve control variceal bleeding compare placebo . On hand , efficacy somatostatin early rebleeding control similar terlipressin . In suspected acute variceal bleeding ( EVB ) , vasoactive drug start soon possible generally prescribed 5 day prevent early rebleeding . Endoscopic variceal ligation ( EVL ) recommend patient EVB best use combination vasoactive drug accord Baveno IV consensus . In contrast consensus recommendation , short-course administration ( 2-day 3-day ) vasoactive drug effective 5-day course control acute EVB use adjuvant therapy EVL . The management acute EVB real world clinical practice may much different recommendation guideline . In Taiwan , National Health Insurance ( NHI ) program use single-payer system , cover 99.9 % nation 's population provide physician high degree freedom choose various medication . Nevertheless , NHI system date provide short-course ( 3 day ) administration vasoactive drug treat acute EBV . This lead u conduct study , aim prospective cohort study assess efficacy safety 3-day somatostatin compare 3-day terlipressin acute EVB patient receive EVL real world situation Taiwan . The preference doctor towards vasoactive drug efficacy vasoactive agent prevent rebleeding analyze . Materials Methods Study Patients From April 2010 April 2015 , cirrhotic patient admit Kaohsiung Veterans General Hospital ( tertiary referral center ) significant upper gastrointestinal bleeding screen . Eligible patient acute EVB non-randomly assign receive early administration somatostatin ( group S ) terlipressin ( group T ) , follow EVL within 24 hour . Inclusion criterion : ( ) acute hemorrhage esophageal varice ( ) ; ( ii ) portal hypertension attribute cirrhosis ; ( iii ) age 20 80 year old . Acute bleed esophageal varix define ooze spurt directly observe endoscopically , red color sign and/or white nipple sign see esophageal varix without potential source bleed identify . Patients exclude meet exclusion criterion follow : ( ) associate hepatocellular carcinoma ( HCC ) Barcelona-Clinic Liver Cancer ( BCLC ) &gt; C ; ( ii ) associate severe illness chronic obstructive pulmonary disease ( COPD ) , septic shock , cerebral vascular event , acute coronary syndrome uremia ; ( iii ) current gastric variceal bleeding ; ( iv ) ever underwent endoscopic injection sclerotherapy ( EIS ) , EVL within 6 month prior current bleeding episode ; ( vii ) ever receive shunt transjugular intrahepatic porto-systemic stent shunt ( TIPS ) procedure ; ( viii ) allergic and/or contraindication vasopressor ; ( ix ) pregnancy . Informed consent give participate patient obtain administration vasoactive agent . This study conform Declaration Helsinki World Medical Association ( 2008 ) approve Institutional Review Board Kaohsiung Veterans General hospital , Taiwan , Republic China ( IRB No . VGHKS99-CT4-20 ) . Study Design In prospective cohort study , eligible patient non-randomly assign two group ( group T : terlipressin group S : somatostatin ) . A decision use vasoactive drug depend favorite participate attend physician request fill enclose questionnaire immediately administration first dose understand underlying reason choose medication . Convenient administration , safety profile , random selection others four selection give . The result select choice document . Patients suspect acute variceal bleeding administer vasoconstrictor , either terlipressin ( Glypressin , Ferring GmbH , Kiel , Germany ) somatostatin ( Somatosan , BAG Health Care GmbH , Lich , Germany ) continue first time . After pre-medicated hyoscine-N-butylbromide intramuscularly ( 20 mg ) , eligible patient underwent emergent endoscopy ( index endoscopy ) within 12 hour admission . Two experienced endoscopists perform emergent EVL enrol patient acute EVB , perform EVL 9 year . Pneumoactive ligation device ( Sumitomo Bakelite Co. , Ltd , Tokyo , Japan ) endoscopes ( GIF XQ260 ; Olympus Co. Ltd , Tokyo , Japan ) apply . The targeted varix suction entrapped cap endoscope . Ligation aim active bleeding site , red color spot white nipple sign procedure . One two rubber band apply ligate target varix . Patients routinely place liquid diet follow 3 day subsequently shift semisolids solid . Somatostatin give intravenous bolus ( 250 μg ) follow 250 μg/hour continue 3 day group S. Terlipressin start 2mg bolus injection follow 1 mg infusion every 6 hour 3 day group T. Both study group administer 40mg pantoprazole intravenously EVL 3 day , follow oral form 12 day hasten process heal ulcer induced ligation . Oral administration non-selective β-blocker consider start day 5 . Prophylactic antibiotic initiate continue 5 day . Elective EVL undertaken interval three four week . The period follow-up 42 day . Study End Points Control initial bleeding define treatment failure occur within 48 hour recruitment . One criterion define failure , whichever occur first : new fresh blood vomitus &gt; 2 hour start vasoactive drug therapeutic endoscopy , hemoglobin drop &gt; 3 gram per deciliter patient transfuse death . An episode clinically significant bleeding define blood transfusion &gt; 2 unit pack red blood cell . Very early rebleeding define acute variceal bleeding occur 48 120 hour control initial acute hemorrhage . Early rebleeding define variceal hemorrhage occur day 3 till day 42 initial bleed arrest . The end point control initial bleeding , early rebleeding , early rebleeding , mortality 6 week , blood transfusion , hospital stay adverse event real world clinical practice . Statistical Analysis By use Student 's two-tailed t-test , quantitative data express mean+ standard deviation compare . X2 Fisher 's exact test use comparison qualitative variable wherever appropriate . The reported p value implement two sided test , wherever appropriate . P-value &lt; 0.05 consider significant . All analysis conduct use SPSS 12.0.1C ( SPSS Inc. , Chicago , IL , USA ) .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Terlipressin</mesh_term>
	<mesh_term>Lypressin</mesh_term>
	<criteria>acute hemorrhage esophageal varice ( ) portal hypertension attribute cirrhosis age 20 80 year old associate hepatocellular carcinoma ( HCC ) BarcelonaClinic Liver Cancer ( BCLC ) &gt; C associate severe illness chronic obstructive pulmonary disease ( COPD ) , septic shock , cerebral vascular event , acute coronary syndrome uremia current gastric variceal bleed ever underwent endoscopic injection sclerotherapy ( EIS ) , EVL within 6 month prior current bleeding episode ever receive shunt transjugular intrahepatic portosystemic stent shunt ( TIPS ) procedure allergic and/or contraindication vasopressor pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>somatostatin</keyword>
	<keyword>variceal bleeding</keyword>
	<keyword>terlipressin</keyword>
</DOC>